Navigation Links
Experimental TB drug effective against resistant and latent mycobacterium tuberculosis

An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers report their results today at the 2006 ASM Biodefense Research Meeting.

"The class of which this compound is the lead has a very different mechanism of action from any other drug currently used to treat tuberculosis. We have identified no cross resistance with existing drugs. Every isolate we have tested so far has been susceptible to this compound," says Nicole Parrish of Johns Hopkins Medical School, a lead researcher on the study.

"This compound (FAS20013) appears to be a potential new drug for treating all forms of tuberculosis, even drug-resistant and latent infections," says Albert Owens, President of FASgen, Inc., the company working to bring the drug to market.

The potent killing activity of FAS20013 is directed specifically against slow growing mycobacteria that cause the disease rather than at a broad array of non-pathogenic organisms, which merely enhances the emergence of drug- resistant strains. No resistance has been encountered to FAS20013 in clinical isolates,. The short-term killing power of FAS20013 is greater than currently used drugs; for example, FAS20013 will kill more organisms in a 4-hour exposure than isoniazid or rifampin can during a 12- to 14-day exposure.

Multiple drug-resistant tuberculosis (MDR-TB) has a fatality rate of 20 to 80 percent. In the United States if a person fails to respond to all therapies and doctors cannot bring the active infection under control, that person must be quarantined indefinitely to prevent the spread of the drug-resistant infection in the population. In the most extreme cases, part of the lung may be surgically removed. It is estimated the cost of treating a single case of MDR-TB can be as much as $250,000.

What makes this drug candidate even more promis
'"/>

Source:American Society for Microbiology


Page: 1 2

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Combination therapy boosts effectiveness of telomere-directed cancer cell death
11. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
Post Your Comments:
(Date:9/17/2014)... "Nature has developed, very cleverly, some lessons on how ... design," said Joseph Shaw, director of the Optical Technology ... and structures at the nanoscale, we,ll discover them." , ... in August during a conference called "The Nature of ... Liang of the University of Arizona College of Optical ...
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2
... of the Santa Cruz Mountains two closely related species of ... very different social lives. The California mouse ( Peromyscus californicus ... mouse ( Peromyscus maniculatus ) is sexually promiscuous. Researchers ... differences in sexual behavior impact the bacteria hosted by each ...
... toward helping people grow big, strong muscles without needing to ... blocking the function of a protein called Grb10 while mice ... muscular than their normal counterparts. This discovery appears in the ... . Outside of aesthetics, this study has important implications for ...
... to common environmental chemicals - polyfluoroalkyl compounds (PFCs) - ... at 20 months of age, according to a study ... online in the August 30 edition of Environmental ... production of fluoropolymers and are found widely in protective ...
Cached Biology News:Monogamy and the immune system 2Monogamy and the immune system 3Monogamy and the immune system 4Monogamy and the immune system 5'Hulk' protein, Grb10, controls muscle growth 2Chemical exposure in the womb from household items may contribute to obesity 2
(Date:9/17/2014)... 2014 A long-term retrospective study of ... (APBI) via interstitial brachytherapy suggests that women younger ... could be suitable to receive the treatment. Current ... these patients in the "unsuitable" category for APBI. ... meeting, Beaumont Health System,s Peter Y. Chen ...
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 ... it won a Small Business Innovation Research (SBIR) grant ... allergy immunotherapy. The award will provide ITI with approximately ... , Tree nuts, a leading cause of food allergy, ... leading cause of anaphylaxis behind peanut allergy. Tree nut ...
(Date:9/17/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, today announced that its ... the United States on the OTCQX ... 17, 2014 on the OTCQX under the symbol SQIDF.  ... Venture Exchange under its existing symbol SQD. ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... , ATLANTA, Sept. 14 CryoLife, Inc. ... medical device and cardiovascular tissue processing company, announced today that it ... Conference at the Grand Hyatt New York in New York City. ... executive officer of CryoLife, Inc., will present Monday, September 21 at ...
... , NATICK, Mass., Sept. ... ) today announced that it has entered into a ... company offering advanced testing solutions for urinary incontinence. ... combines staffing, equipment, supplies and results analysis, helping to ...
... , HOLDEN, Mass., Sept. ... appointment of Elkan Gamzu, Ph.D. as Chairman to its ... years of pharmaceutical and biotechnology experience and has held ... President of Project Management at Millenium Pharmaceuticals, CEO of ...
Cached Biology Technology:CryoLife to Present at UBS Global Life Sciences Conference 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
... a partial recombinant MAK. Immunogen: ... partial recombinant protein with GST tag. ... Accession: BC039825 Protein Accession ... 154235, GeneID: 4117 ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Biology Products: